Aliases & Classifications for Polyneuropathy

Summaries for Polyneuropathy

Disease Ontology : 12 A peripheral system disease that is characterized by is damage affecting peripheral nerves (peripheral neuropathy) in roughly the same areas on both sides of the body, featuring weakness, numbness, pins-and-needles, and burning pain.

MalaCards based summary : Polyneuropathy, also known as polyneuropathies, is related to amyloidosis, hereditary, transthyretin-related and demyelinating polyneuropathy, and has symptoms including neuralgia An important gene associated with Polyneuropathy is GDAP1 (Ganglioside Induced Differentiation Associated Protein 1), and among its related pathways/superpathways are Guidance Cues and Growth Cone Motility and Neural Crest Differentiation. The drugs Imipramine and Pregabalin have been mentioned in the context of this disorder. Affiliated tissues include liver, skin and testes, and related phenotypes are cellular and behavior/neurological

Wikipedia : 72 Polyneuropathy (poly- + neuro- + -pathy) is damage or disease affecting peripheral nerves (peripheral... more...

Related Diseases for Polyneuropathy

Diseases in the Polyneuropathy family:

Polyneuropathy Due to Drug Chronic Polyneuropathy

Diseases related to Polyneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 586)
# Related Disease Score Top Affiliating Genes
1 amyloidosis, hereditary, transthyretin-related 33.7 APOA1 GSN TTR
2 demyelinating polyneuropathy 33.7 MAG PMP22 TTR
3 chronic polyneuropathy 33.4 CD40LG MAG
4 amyloidosis, finnish type 33.3 GSN TTR
5 neuropathy, hereditary, with liability to pressure palsies 32.5 GDAP1 MPZ PMP22
6 hereditary neuropathy with liability to pressure palsy 32.4 MPZ PMP22
7 guillain-barre syndrome 32.3 CD40LG MBP MPZ PMP22
8 charcot-marie-tooth disease, demyelinating, type 1b 32.1 MPZ PMP22
9 diabetic neuropathy 32.1 AKR1B1 MPZ PMP22
10 polyradiculoneuropathy 31.9 MBP MPZ PMP22
11 miller fisher syndrome 31.0 CD40LG MAG
12 neuropathy 30.9 GDAP1 MPZ MT-ATP6 PMP22 PNPLA6
13 charcot-marie-tooth disease, demyelinating, type 1a 30.7 GDAP1 MPZ PMP22
14 neuropathy, congenital hypomyelinating or amyelinating, autosomal recessive 30.5 GDAP1 MPZ PMP22
15 amyloidosis 30.5 APOA1 GSN TTR
16 charcot-marie-tooth disease, demyelinating, type 1f 30.4 MPZ PMP22
17 hereditary amyloidosis 30.2 APOA1 GSN TTR
18 foot drop 30.1 MPZ PMP22
19 charcot-marie-tooth disease 30.0 GDAP1 MBP MPZ MT-ATP6 PMP22
20 charcot-marie-tooth disease, x-linked dominant, 1 30.0 GDAP1 MPZ
21 amyloid neuropathy 29.9 APOA1 GSN TTR
22 charcot-marie-tooth disease and deafness 29.9 GDAP1 MPZ PMP22
23 mononeuritis multiplex 29.9 CD40LG MAG
24 hereditary neuropathies 29.7 MAG MBP MPZ PMP22
25 hypertrophic neuropathy of dejerine-sottas 29.6 GDAP1 MPZ PMP22
26 chronic inflammatory demyelinating polyradiculoneuropathy 29.6 MBP MPZ PMP22
27 roussy-levy hereditary areflexic dystasia 29.5 GDAP1 MPZ MT-ATP6 PMP22
28 optic neuritis 29.3 MAG MBP MPZ
29 charcot-marie-tooth disease, axonal, type 2e 29.3 GDAP1 MPZ PMP22
30 neuritis 29.1 MAG MBP MPZ PMP22
31 demyelinating disease 29.1 CD40LG MAG MBP
32 cryoglobulinemia, familial mixed 29.0 CD40LG IFNA2
33 peripheral nervous system disease 28.2 CD40LG GDAP1 MAG MPZ PMP22 PNPLA6
34 chronic inflammatory demyelinating polyneuropathy 12.4
35 polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract 12.3
36 hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy 12.2
37 diabetic polyneuropathy 12.2
38 critical illness polyneuropathy 12.2
39 ataxia and polyneuropathy, adult-onset 12.2
40 polyendocrine-polyneuropathy syndrome 12.1
41 subacute inflammatory demyelinating polyneuropathy 12.0
42 paraneoplastic polyneuropathy 12.0
43 charcot-marie-tooth disease, x-linked recessive, 5 11.9
44 polyneuropathy due to drug 11.9
45 axonal polyneuropathy associated with igg/igm/iga monoclonal gammopathy 11.9
46 polyneuropathy associated with igm monoclonal gammapathy with anti-mag 11.9
47 aplasia of extensor muscles of fingers, unilateral, with generalized polyneuropathy 11.9
48 poems syndrome 11.9
49 guillain-barre syndrome, familial 11.8
50 polyneuropathy-intellectual disability-acromicria-premature menopause syndrome 11.8

Graphical network of the top 20 diseases related to Polyneuropathy:



Diseases related to Polyneuropathy

Symptoms & Phenotypes for Polyneuropathy

UMLS symptoms related to Polyneuropathy:


neuralgia

MGI Mouse Phenotypes related to Polyneuropathy:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.1 APOA1 CD40LG CD59 GDAP1 GSN MBP
2 behavior/neurological MP:0005386 10.07 AKR1B1 ARSA GDAP1 MAG MBP MPZ
3 homeostasis/metabolism MP:0005376 9.86 ABHD12 ACHE AKR1B1 APOA1 ARSA CD40LG
4 hematopoietic system MP:0005397 9.85 SLC25A19 MBP MPZ ABHD12 ACHE ARSA
5 hearing/vestibular/ear MP:0005377 9.73 ABHD12 ACHE ARSA MAG MBP PMP22
6 nervous system MP:0003631 9.44 PNPLA6 SLC25A19 TUBB3 ABHD12 ACHE ARSA

Drugs & Therapeutics for Polyneuropathy

Drugs for Polyneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 309)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Imipramine Approved Phase 4 50-49-7 3696
2
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1 148553-50-8 5486971
3
Lidocaine Approved, Vet_approved Phase 4,Phase 2 137-58-6 3676
4
Lenalidomide Approved Phase 4,Phase 2 191732-72-6 216326
5 Piracetam Approved, Investigational Phase 4,Phase 2 7491-74-9
6
Citalopram Approved Phase 4 59729-33-8 2771
7
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
8
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
9
Mexiletine Approved, Investigational Phase 4,Phase 2 31828-71-4 4178
10
Norepinephrine Approved Phase 4,Phase 2 51-41-2 439260
11
Nortriptyline Approved Phase 4 72-69-5 4543
12
Capsaicin Approved Phase 4,Phase 2,Phase 3 404-86-4 1548943
13
Acetylcholine Approved Phase 4,Phase 2,Phase 3,Early Phase 1 51-84-3 187
14
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
15
Oxcarbazepine Approved Phase 4 28721-07-5 34312
16
alemtuzumab Approved, Investigational Phase 4,Phase 2 216503-57-0
17
Ranolazine Approved, Investigational Phase 4 95635-55-5, 142387-99-3 56959
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3 59-30-3 6037
19 Etiracetam Investigational Phase 4,Phase 2 33996-58-6
20 Adrenergic Agents Phase 4,Phase 3,Phase 2
21 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
22 Anti-Anxiety Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1
24 Antidepressive Agents Phase 4,Phase 2
25 Antidepressive Agents, Tricyclic Phase 4
26 calcium channel blockers Phase 4,Phase 3,Phase 2,Phase 1
27 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
28 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
29 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
31 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
33 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Nootropic Agents Phase 4,Phase 2,Phase 3
35 Protective Agents Phase 4,Phase 2,Phase 3,Early Phase 1
36 Autonomic Agents Phase 4,Phase 3,Phase 2
37 Platelet Aggregation Inhibitors Phase 4,Phase 2
38 Anti-Arrhythmia Agents Phase 4,Phase 2
39 Diuretics, Potassium Sparing Phase 4,Phase 2
40 Sodium Channel Blockers Phase 4,Phase 2
41 Antioxidants Phase 4,Phase 2,Phase 3,Early Phase 1
42 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1
43 Thioctic Acid Phase 4,Phase 2,Phase 3
44 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1
45 Vitamin B Complex Phase 4,Phase 2,Phase 3
46 Vitamins Phase 4,Phase 2,Phase 3,Phase 1
47 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3
48 Anesthetics Phase 4,Phase 2
49 Anesthetics, Local Phase 4,Phase 2
50 Angiogenesis Inhibitors Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 343)

# Name Status NCT ID Phase Drugs
1 Imipramine and Pregabalin Combination in Painful Polyneuropathy Unknown status NCT01047488 Phase 4 Imipramine;Pregabalin;Imipramine, pregabalin;Placebo
2 Muscular Electrostimulation of the Sedated and Mechanically Ventilated Critically Ill Patient. Analysis of the Effect on Acquired Muscular Weakness and Its Clinical Consequences. Unknown status NCT02033057 Phase 4
3 Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic Neuropathy Unknown status NCT01770964 Phase 4 Pregabalin;placebo
4 Effects of Pregabalin on Mechanical Hyperalgesia Unknown status NCT00310583 Phase 4 Pregabalin
5 Levetiracetam for Painful Polyneuropathy Completed NCT00286260 Phase 4 levetiracetam
6 Escitalopram as a Treatment for Pain in Polyneuropathy Completed NCT00162968 Phase 4 escitalopram
7 Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the Philippines Completed NCT01076478 Phase 4 Cilostazol
8 Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations Completed NCT02260388 Phase 4 Nortriptyline;Duloxetine;Pregabalin;Mexiletine
9 A Study to Compare QUTENZA With Pregabalin for the Treatment of Peripheral Neuropathic Pain (PNP) After 8 Weeks of Treatment Completed NCT01713426 Phase 4 Qutenza;Pregabalin
10 Alpha Lipoic Acid for Treatment of Diabetic Neuropathy Completed NCT02439879 Phase 4 Alpha lipoic acid
11 Botulinum Toxin in Peripheral Neuropathic Pain Completed NCT01251211 Phase 4 botulinum toxin type A
12 Oxcarbazepine for the Treatment of Chronic Peripheral Neuropathic Pain Completed NCT01302275 Phase 4 Oxcarbazepine
13 Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy Completed NCT00903851 Phase 4 Lidoderm
14 Study To Evaluate The Safety And Efficacy Of Lenalidomide For Refractory Cutaneous Lupus Completed NCT01408199 Phase 4 Lenalidomide
15 Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder Completed NCT00844194 Phase 4 Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 90 mg QD;Duloxetine 90 mg QD;Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 120 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 120 mg QD
16 Effect of Pulsing Electrical Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study Completed NCT00614341 Phase 4
17 Postoperative Alpha Lipoic Acid in the Carpal Tunnel Syndrome: a Randomized Controlled Trial. Completed NCT01895621 Phase 4
18 IVIg for Demyelination in Diabetes Mellitus Recruiting NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
19 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Active, not recruiting NCT03226119 Phase 4
20 Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy Terminated NCT00832572 Phase 4 Ranolazine;Placebo
21 Efficacy, Safety, Tolerability and Pharmacokinetics of Concomitant Administration of Tramadol With Duloxetine or Pregabalin Withdrawn NCT01116531 Phase 4 Tramadol;Duloxetine;Pregabalin
22 Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) Withdrawn NCT01757574 Phase 4 Alemtuzumab infusion
23 Lidocaine and Triamcinolone vs Saline Trigger Point Injection for Treatment of Chronic Abdominal Wall Pain Withdrawn NCT02748395 Phase 4 Triamcinolone;Lidocaine
24 Efficacy and Safety Study of Thioctacid Oral Tablets 600mg to Treat Chinese Diabetic Patients With Distal Symmetric Polyneuropathy Unknown status NCT01224353 Phase 2, Phase 3 lipoic acid
25 Effects of Benfotiamine on Intraepidermal Nerve Fiber Density (IENFD) Unknown status NCT01868191 Phase 3 Benfotiamine;Placebo for benfotiamine
26 Treadmill, Stretching and Proprioceptive Exercise (TreSPE) Rehabilitation Program for Charcot−Marie−Tooth Neuropathy Type 1A (CMT1A) Unknown status NCT01289704 Phase 2, Phase 3
27 Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
28 Actovegin® Versus Placebo in Patients With Diabetic Polyneuropathy (AV-007-IM) Completed NCT00483730 Phase 3 Deproteinised hemoderivative of calf blood (Actovegin)
29 RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy Completed NCT00259974 Phase 3 Rituximab
30 Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2) Completed NCT00977483 Phase 3 Thioctic Acid;Placebo
31 Evaluating the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy Completed NCT00927914 Phase 2, Phase 3 Ranirestat;Placebo
32 Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01184846 Phase 3
33 Efficacy and Safety of IONIS-TTR Rx in Familial Amyloid Polyneuropathy Completed NCT01737398 Phase 3 IONIS-TTR Rx;Placebo
34 Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
35 The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin Completed NCT01435655 Phase 3 tafamidis
36 An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy Completed NCT00791492 Phase 2, Phase 3 Fx-1006A
37 Neuropathic Pain Management Completed NCT01263132 Phase 3 F0434;Gabapentin
38 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) Completed NCT01545076 Phase 3
39 Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT02027701 Phase 3
40 Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis Completed NCT00409175 Phase 2, Phase 3 Fx-1006A;Placebo
41 Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy Completed NCT00101426 Phase 3 ranirestat, (AS-3201)
42 Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
43 Efficacy and Safety Study of Topical Capsaicin in Painful Diabetic Neuropathy Completed NCT00993070 Phase 2, Phase 3 Capsaicin;placebo
44 Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) Completed NCT00328601 Phase 3 Thioctic Acid
45 Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy Completed NCT00004939 Phase 3 ,4-diaminopyridine
46 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin
47 The Effect of Diflunisal on Familial Amyloidosis Completed NCT00294671 Phase 2, Phase 3 diflunisal
48 Evaluate The Efficacy and Safety Of Pregabalin In Prevention, Reduction of Oxaliplatin-Induced Painful Neuropathy Completed NCT01450163 Phase 3 Pregabalin, Oxaliplatin;Placebo , Oxaliplatin
49 APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis Completed NCT01960348 Phase 3 patisiran (ALN-TTR02);Sterile Normal Saline (0.9% NaCl)
50 Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy Completed NCT00064623 Phase 3 Capsaicin Dermal Patch

Search NIH Clinical Center for Polyneuropathy

Cochrane evidence based reviews: polyneuropathies

Genetic Tests for Polyneuropathy

Genetic tests related to Polyneuropathy:

# Genetic test Affiliating Genes
1 Polyneuropathy 28

Anatomical Context for Polyneuropathy

MalaCards organs/tissues related to Polyneuropathy:

38
Liver, Skin, Testes, Spinal Cord, Brain, Endothelial, Heart

Publications for Polyneuropathy

Articles related to Polyneuropathy:

(show top 50) (show all 2171)
# Title Authors Year
1
Specific symptoms may discriminate between fibromyalgia patients with vs without objective test evidence of small-fiber polyneuropathy. ( 29430562 )
2018
2
Bilateral facial nerve palsies secondary to chronic inflammatory demyelinating polyneuropathy following adalimumab treatment. ( 29179036 )
2018
3
A brain-based pain facilitation mechanism contributes to painful diabetic polyneuropathy. ( 29346515 )
2018
4
Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab. ( 29382383 )
2018
5
Cerebrospinal Fluid Cytokine Expression Profile in Multiple Sclerosis and Chronic Inflammatory Demyelinating Polyneuropathy. ( 29182448 )
2018
6
Impaired thiol-disulphide homeostasis in patients with axonal polyneuropathy. ( 29359643 )
2018
7
Diabetic polyneuropathy, deep white matter lesions, and carotid atherosclerosis: is there any association? ( 29063451 )
2018
8
Is Regenerative Medicine Ready for Prime Time in Diabetic Polyneuropathy? ( 29383511 )
2018
9
Laboratory Abnormalities in Polyneuropathy and Electrophysiological Correlations. ( 29433597 )
2018
10
Acute mitochondrial myopathy with respiratory insufficiency and motor axonal polyneuropathy. ( 28969510 )
2018
11
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. ( 29122523 )
2018
12
Standing postural reaction to visual and proprioceptive stimulation in chronic acquired demyelinating polyneuropathy. ( 29313871 )
2018
13
Difference in normal limit values of nerve conduction parameters between Westerner and Japanese people may need to be considered when diagnosing diabetic polyneuropathy using a Point-of-Care Sural Nerve Conduction Device(NC-stat<sup>a98</sup>/DPNCheck<sup>a8c</sup>). ( 29430866 )
2018
14
Assessment of vestibular-evoked myogenic potentials and video head impulse test in type 2 diabetes mellitus patients with or without polyneuropathy. ( 29330601 )
2018
15
The Effect of Caudal Epidural Pulsed Radiofrequency Stimulation in Patients with Refractory Chronic Idiopathic Axonal Polyneuropathy. ( 29357341 )
2018
16
Elevated leukocyte count in cerebrospinal fluid of patients with chronic inflammatory demyelinating polyneuropathy. ( 29341326 )
2018
17
Physical interventions for patients suffering from chemotherapy-induced polyneuropathy. ( 29374785 )
2018
18
A chemometric approach for characterization of serum transthyretin in familial amyloidotic polyneuropathy type I (FAP-I) by electrospray ionization-ion mobility mass spectrometry. ( 29426546 )
2018
19
Sensory nerve degeneration in a mouse model mimicking early manifestations of familial amyloid polyneuropathy due to transthyretin Ala97Ser. ( 29423915 )
2018
20
Small Fiber Polyneuropathy Is Prevalent in Patients Experiencing Complex Chronic Pelvic Pain. ( 29447372 )
2018
21
Elevated serum levels of endothelin-1 in patients with chronic inflammatory demyelinating polyneuropathy. ( 29137897 )
2018
22
Polyneuropathy and myopathy in beta-thalassemia major patients. ( 29427184 )
2018
23
Outcome in chronic inflammatory demyelinating polyneuropathy from a Malaysian centre over sixteen years. ( 29398193 )
2018
24
Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. ( 29343286 )
2018
25
Lenalidomide-Induced Ischemic Cerebrovascular Disease in Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome. ( 29395638 )
2018
26
Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy. ( 29122522 )
2018
27
IVIg for apparently autoimmune small-fiber polyneuropathy: first analysis of efficacy and safety. ( 29403541 )
2018
28
Vestibular impairment in chronic inflammatory demyelinating polyneuropathy. ( 29260355 )
2018
29
Long-term effects of liver transplantation on small-fiber dysfunction in Japanese transthyretin (ATTR) V30M hereditary amyloidosis with polyneuropathy (FAP). ( 28434340 )
2017
30
A GJA9 frameshift variant is associated with polyneuropathy in Leonberger dogs. ( 28841859 )
2017
31
Patterns of cutaneous nerve fibre loss and regeneration in type 2 diabetes with painful and painless polyneuropathy. ( 28914336 )
2017
32
Myasthenia gravis and chronic inflammatory demyelinating polyneuropathy in the same patientA -A a case report. ( 29073825 )
2017
33
An Adult with Polyneuropathy and Hypogonadism due to Poems Syndrome. ( 29056130 )
2017
34
Diabetic polyneuropathy is a risk factor for decline of lower extremity strength in patients with type 2 diabetes. ( 28296226 )
2017
35
Do we underestimate influences of diabetic mononeuropathy or polyneuropathy on hand functional performance and life quality? ( 28267271 )
2017
36
Unconventional treatments for chronic inflammatory demyelinating polyneuropathy. ( 29043889 )
2017
37
Cardio-Ankle Vascular Index and Indices of Diabetic Polyneuropathy in Patients with Type 2 Diabetes. ( 28573145 )
2017
38
Chronic inflammatory demyelinating polyneuropathy. ( 28763304 )
2017
39
Chronic Inflammatory Demyelinating Polyneuropathy Variant with Creatine-Kinase Elevation and Vanishing Effect of Immunoglobulins. ( 28747620 )
2017
40
A prospective study comparing tryptophan immunoadsorption with therapeutic plasma exchange for the treatment of chronic inflammatory demyelinating polyneuropathy. ( 28485075 )
2017
41
Tafamidis for a Transplant Patient with Transthyretin Amyloid Polyneuropathy. ( 28884984 )
2017
42
Brainstem encephalitis and acute polyneuropathy associated with hepatitis E infection. ( 28899886 )
2017
43
Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with antineurofascin-155 and anticontactin-1 antibodies. ( 28073817 )
2017
44
Functional outcome of critical illness polyneuropathy in patients affected by severe brain injury. ( 28417610 )
2017
45
Hereditary Sensory Polyneuropathy, Pain Insensitivity and Global Developmental Delay due to Novel Mutation in PRDM12 Gene. ( 28050684 )
2017
46
Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial. ( 28768822 )
2017
47
Changes in spatiotemporal gait parameters following intravenous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy. ( 28085193 )
2017
48
Acute Demyelinating Polyneuropathy as Presentation of Hereditary Neuropathy With Liability to Pressure Palsies in a Patient Who Exercised Regularly in the Army. ( 28538254 )
2017
49
Two different causes in a patient with distal symmetric axonal polyneuropathy: Churg-Strauss syndrome and multiple myeloma, coincidental or associated with each other? ( 28332041 )
2017
50
Chronic Inflammatory Demyelinating Polyneuropathy: A Case Series. ( 29143254 )
2017

Variations for Polyneuropathy

ClinVar genetic disease variations for Polyneuropathy:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 GDAP1 NM_018972.2(GDAP1): c.715C> T (p.Leu239Phe) single nucleotide variant Pathogenic rs104894080 GRCh37 Chromosome 8, 75276240: 75276240

Expression for Polyneuropathy

Search GEO for disease gene expression data for Polyneuropathy.

Pathways for Polyneuropathy

Pathways related to Polyneuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.5 GDAP1 GSN MAG
2 11.14 MBP MPZ PMP22
3
Show member pathways
10.43 RBP4 TTR
4 9.53 MAG MBP

GO Terms for Polyneuropathy

Cellular components related to Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.97 ACHE APOA1 ARSA CD40LG CD59 GSN
2 extracellular space GO:0005615 9.65 ACHE AKR1B1 APOA1 ARSA CD40LG CD59
3 myelin sheath GO:0043209 9.46 GSN MAG MBP MPZ
4 Schmidt-Lanterman incisure GO:0043220 9.26 AKR1B1 MAG
5 compact myelin GO:0043218 8.8 MAG MBP PMP22

Biological processes related to Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to ethanol GO:0045471 9.58 ARSA GSN RBP4
2 negative regulation of viral entry into host cell GO:0046597 9.37 GSN IFNA2
3 cell-cell adhesion via plasma-membrane adhesion molecules GO:0098742 9.32 MAG MPZ
4 glycerophospholipid catabolic process GO:0046475 9.26 ABHD12 PNPLA6
5 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.16 APOA1 MBP
6 retinoid metabolic process GO:0001523 9.13 APOA1 RBP4 TTR
7 myelination GO:0042552 8.8 MBP MPZ PMP22

Sources for Polyneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....